(Q37097043)

18 August 2017

0 references

1 reference

title

BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE. (English)

1 reference

18 August 2017

Claus G Roehrborn

1

1 reference

18 August 2017

1 March 2008

1 reference

18 August 2017

1 reference

18 August 2017

101 Suppl 3

1 reference

18 August 2017

17-21

1 reference

Natural history of prostatism: impact of urinary symptoms on quality of life in 2115 randomly selected community men.

18 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07497.X

Quality-of-life impact of lower urinary tract symptom severity: results from the Health Professionals Follow-up Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07497.X

Natural history of prostatism: longitudinal changes in voiding symptoms in community dwelling men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07497.X

The natural history of benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07497.X

Distribution of post-void residual urine volume in randomly selected men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07497.X

The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07497.X

Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07497.X

The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07497.X

Definition of at-risk patients: baseline variables

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07497.X

Definition of at-risk patients: dynamic variables

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07497.X

Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07497.X

Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07497.X

10.1111/J.1464-410X.2008.07497.X

21 January 2018

Identifiers

DOI

1 reference

18 August 2017

1 reference

PubMed ID

18307681